Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | PHASE3 | COMPLETED | 236 | — | — | Sep 1, 2006 | Jan 1, 2011 | May 1, 2012 | 25 | United States, Austria +5 |
| Arm | Type | Description |
|---|---|---|
| Best Standard of Care | ACTIVE_COMPARATOR | Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center. |
| NovoTTF-100A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NovoTTF-100A | DEVICE | multiple four-week courses of continuous NovoTTF-100A treatment |
Inclusion Criteria: * Pathological evidence of GBM using WHO classification criteria. * \> 18 years of age. * Not a candidate for further radiotherapy or additional resection of residual tumor. * Patients with disease progression (by Macdonald criteria i.e., \> 25% or new lesion) documented by CT o...